Skip to main content
INMDInMode Ltd.Sell5.5·$12.42
SellModerate Confidence

Thesis pillars

  • Best In Class Margins Valuation→Stable
  • Weak Growth Falling Estimates→Stable
  • Price Above Analyst Target↑Improving
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Oct 24, 2026

Full reasoning →

Open full analysis

InMode Ltd. (INMD) Stock Analysis

Falling Knife setup · Inst Constrain edge

SellValueQualityModerate Confidence

Healthcare · Medical Devices

Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.... Read more

$12.42+0.4% A.UpsideScore 5.5/10#25 of 62 Medical Devices
QualityF-score7 / 9FCF yield5.49%
Stop $12.03Analyst target $12.47(−15% haircut)A.R:R 0.1:1
Analyst consensus$14.67+18.1%3 analysts with price targets
$12.47Analyst target
$12.42price
$14.67mean
$15

Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Score 5.5/10, moderate confidence.

Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 21, 2026

Recent Developments — InMode Ltd.

Latest news

Latest item Nov 21, 2026 · Generated 2026-11-22T11:52:07Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 9, 202778d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.8
Strong earnings beat streak (3/4)
Attractive valuation
Risks
Analyst target reached - limited upside remaining
Weak growth
Negative momentum

Key Metrics

P/E (TTM)10.4
P/E (Fwd)9.1
Mkt Cap$715M
EV/EBITDA3.0
Profit Mgn19.9%
ROE11.4%
Rev Growth-1.1%
Beta1.96
DividendNone
Analysts with ratings10

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C7.57bearish
IV82%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Macd
2.4
Rsi
3.5
Volume
4.1
Volume distribution (falling OBV)Below 200-MA, MA slope -1.2%/30d — confirmed downtrend

Revenue shrinking — -1.1% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
2.2
Earnings Growth
4.8
Declining revenue: -1%
GatesMomentum 2.4<4.5A.R:R 0.1 < 1.5@spotDeath cross (50MA < 200MA)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
33 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $12.40Resistance $14.54

Price Targets

$12
$12
A.Upside+0.4%
A.R:R0.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCrisis

Risk Alerts

! Target reached (0.4% upside)
! momentum at 2.4 (below the engine's 4.5 threshold)
! asymmetry at 0.1 (below the engine's 1.5 threshold)@spot

Earnings

B
B
B
M
3/4 beats
Next Earnings2027-02-09 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is INMD stock a buy right now?

Sell if holding. Analyst target reached at $12.42 — A.R:R 0.1:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Prior stop was $12.03. Score 5.5/10, moderate confidence.

What is the INMD stock price target?

Analyst target: $12.47 (+0.4% upside). Prior stop was $12.03. Stop-loss: $12.03.

What are the risks of investing in INMD?

Analyst target reached - limited upside remaining; Weak growth; Negative momentum.

Is INMD overvalued or undervalued?

InMode Ltd. trades at a P/E of 10.4 (forward 9.1). TrendMatrix value score: 8.4/10. Verdict: Sell.

What do analysts say about INMD?

10 analysts rate INMD, with a consensus score of 2.5/5. 3 analysts publish price targets averaging $15.

What does InMode Ltd. do?InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its...

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

Related stocks: DCTH (Delcath Systems, Inc.) · MASS (908 Devices Inc.) · BVS (Bioventus Inc.) · SENS (Senseonics Holdings, Inc.) · BWAY (Brainsway Ltd.)
Home › Stocks › INMD

Latest news

Latest News

Kalkine Media116d ago
MarketBeat116d ago
MarketBeat116d ago
Dars.gov.et124d ago
TradingKey115d ago
TradingKey115d ago
TradingKey122d ago
TradingKey119d ago
TradingKey120d ago
TradingKey120d ago
MarketBeat120d ago
TradingKey120d ago
Po-news-eg.net120d ago
TradingKey118d ago
TradingKey118d ago
TipRanks125d agoMerger Acquisition
ACCESS Newswire125d agoLegal
Ad-hoc-news.de125d ago
TradingKey121d ago
TradingKey121d ago
Loading more...